Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...
Zacks Investment Research on MSN8d
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's DiseaseJohnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, ...
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...
Medpage Today on MSN5mon
Nipocalimab Shows Sustained Efficacy in Myasthenia GravisSAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III ...
Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...
House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...
The Fast Track designation from the FDA facilitates rapid development and expedites the review of drug candidates that are being developed to treat ... diseases. The company is evaluating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback